A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
R-Pharm
Eli Lilly and Company
MOMA Therapeutics
National Cancer Institute (NCI)
University of California, Irvine
Novartis
Novartis
M.D. Anderson Cancer Center
SN BioScience
City of Hope Medical Center
M.D. Anderson Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Toray Industries, Inc
Jiangsu Hansoh Pharmaceutical Co., Ltd.
IGM Biosciences, Inc.
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Canadian Cancer Trials Group
Boehringer Ingelheim
Sumitomo Pharma Co., Ltd.
Fujian Cancer Hospital
NYU Langone Health
Herlev Hospital
Gilead Sciences
National Institutes of Health Clinical Center (CC)
mAbxience Research S.L.
University of Chicago
University of California, Davis
Merck Sharp & Dohme LLC
Merrimack Pharmaceuticals
GlaxoSmithKline
Mayo Clinic
Genentech, Inc.
Northwestern University
University of Kansas Medical Center
University of Chicago
Genentech, Inc.
Merrimack Pharmaceuticals
Jiangsu Simcere Pharmaceutical Co., Ltd.
Amgen
Eli Lilly and Company
Daiichi Sankyo
University of Colorado, Denver
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Novartis